Pregled bibliografske jedinice broj: 1096778
Hybrid quinazoline 1,3,5-triazines as epidermal growth factor receptor (EGFR) inhibitors with anticancer activity: design, synthesis, and computational study
Hybrid quinazoline 1,3,5-triazines as epidermal growth factor receptor (EGFR) inhibitors with anticancer activity: design, synthesis, and computational study // ChemMedChem, 16 (2021), 5; 822-838 doi:10.1002/cmdc.202000646 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1096778 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Hybrid quinazoline 1,3,5-triazines as epidermal
growth factor receptor (EGFR) inhibitors with
anticancer activity: design, synthesis, and
computational study
Autori
Pathak, Prateek ; Rimac, Hrvoje ; Grishina, Maria ; Verma, Amita ; Potemkin, Vladimir
Izvornik
ChemMedChem (1860-7179) 16
(2021), 5;
822-838
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
EGFR inhibitors ; synthesis ; molecular modelling ; in vitro assays ; in vivo assays
Sažetak
We report a series of hybrid quinazoline-1, 3, 5- triazine derivatives as EGFR inhibitors, which were synthesized and tested using a variety of in vitro, in silico, and in vivo studies. The derivatives were found to be active against different cancer and non-toxic against normal cell lines, with compounds 7c, 7d, 7e, and 7j being the most potent ones. The derivatives were also evaluated for angiogenesis inhibition potency in chicken eggs and molecular docking and dynamics simulation studies were carried out to elucidate fundamental substituent groups essential for their bioactivity. Additionally, a SAR study of the derivatives was performed for future compound optimization. These studies suggested that the derivatives have a high affinity towards EGFR with favourable pharmacological properties. The most active compound (7e) was further evaluated for in vivo anticancer activity against DMBA induced tumour in female Sprague-Dawley rats as well as its effects on plasma antioxidant status, biotransformation enzymes, and lipid profile. The study suggested that the 7e compound has lead properties against breast cancer and can serve as a starting compound for further development of anti-EGFR compounds.
Izvorni jezik
Engleski
Znanstvena područja
Kemija, Interdisciplinarne prirodne znanosti, Farmacija
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE